ABSTRACT
The effect of Hypericum perforatum extract (LI 160) at a dose that exerts an antidepressive-like effect was studied in mice in the marble-burying test. Acute Hypericum perforatum (150, 300 and 500 mg/kg, p.o.) reduced immobility time in the forced swimming test. The number of marbles buried, but not locomotor activity, was reduced by acute treatment with Hypericum perforatum (150 and 300 mg/kg, p.o.). However, this effect was not seen after chronic treatment (21 days) with Hypericum perforatum (300 mg/kg, p.o.). Thus, Hypericum perforatum extract, at antidepressant dose, exerts an acute anxiolytic drug effect on the marble-burying test, which could indicate a potential anti-obsessive effect, although the development of tolerance could be an important drawback.
Subject(s)
Antidepressive Agents/pharmacology , Behavior, Animal/drug effects , Depression/prevention & control , Hypericum , Phytotherapy , Plant Extracts/pharmacology , Administration, Oral , Animals , Antidepressive Agents/administration & dosage , Antidepressive Agents/therapeutic use , Dose-Response Relationship, Drug , Male , Mice , Motor Activity , Plant Extracts/administration & dosage , Plant Extracts/therapeutic use , SwimmingABSTRACT
It has been previously shown that oxcarbazepine (OXCBZ), a keto-analogue of carbamazepine, exhibits an antidepressive-like effect profile in the learned helplessness and forced swimming test (FST). Since carbamazepine possesses dopaminergic effect, the present study was carried out to evaluate the extent to which the antidepressive effect of OXCBZ might be mediated by dopaminergic system. Thus, the effects of OXCBZ in haloperidol-induced catalepsy and apomorphine-induced stereotypy were studied. The anti-immobility effect of OXCBZ in the FST was also evaluated in haloperidol pre-treated rats. OXCBZ (40 and 80 mg/kg, i.p.) dose-dependently reduced the catalepsy induced by haloperidol (2.0 mg/kg, i.p.). Moreover, OXCBZ (80 mg/kg, but not 20 or 40 mg/kg, i.p.) increased the intensity of apomorphine-induced stereotypy (0.6 mg/kg, s.c.). Finally, it was observed that the combination of OXCBZ (80 mg/kg, i. p.) and haloperidol (0.5 mg/kg, i.p.) antagonized the anti-immobility effect of OXCBZ and further increased the immobility time when compared to haloperidol alone. Haloperidol alone (0.5 or 1. 0 mg/kg) did not change the immobility time. Thus, these results suggest that OXCBZ could enhance dopaminergic neurotransmission, which might mediate its antidepressive-like effect.
Subject(s)
Antidepressive Agents/therapeutic use , Carbamazepine/analogs & derivatives , Carbamazepine/therapeutic use , Receptors, Dopamine/metabolism , Animals , Antidepressive Agents/pharmacology , Apomorphine , Carbamazepine/pharmacology , Catalepsy/chemically induced , Catalepsy/drug therapy , Disease Models, Animal , Dopamine Antagonists/therapeutic use , Haloperidol , Male , Neurotransmitter Agents , Oxcarbazepine , Rats , Rats, Wistar , Receptors, Dopamine/drug effects , Stereotypic Movement Disorder/chemically induced , Stereotypic Movement Disorder/drug therapy , Swimming/psychologyABSTRACT
The effect of oxcarbazepine was evaluated in two tests of depression (forced swimming and learned helplessness) and in the open-field test. Acute (three times over 24 h) oxcarbazepine 80 mg/kg (but not 40 mg/kg) decreased immobility time in the forced swimming test. In the learned helplessness test, 4 days of treatment with oxcarbazepine 80 mg/kg reversed the deficits induced by foot-shock in rats submitted to the two-way active avoidance test. Oxcarbazepine 80 mg/kg did not modify the behaviour of rats in the open-field test, an indication that, at this dose, oxcarbazepine did not show a locomotor stimulatory effect. Thus, the data of the present study suggest that oxcarbazepine has a potential antidepressive effect.
